Cardiovascular Research Using the Korean National Health Information Database

et al. 2021

Ann Clin Transl Neurol

Self Cite

ObjectiveParkinson’s disease (PD) is the second most common neurodegenerative disorder associated with various morbidities. Although the relationship between cardiovascular disease and PD has been studied, a paucity of information on PD and atrial fibrillation (AF) association exists. Thus, we aimed to investigate whether patients with PD have an increased risk of AF.MethodsThis study included 57,585 patients with newly diagnosed PD (≥40‐year‐old, mean age 69.7 years, men 40.2%) and without a history of AF from the Korean National Health Insurance Service (NHIS) database between 2010 and 2015. Furthermore, an equal number of age‐ and sex‐matched subjects without PD were selected for comparison. The primary outcome was new‐onset AF.ResultsDuring the mean follow‐up period of 3.4 ± 1.8 years, AF was newly diagnosed in 3,665 patients. A significantly higher incidence rate of AF was noted among patients with PD than among patients without PD (10.75 and 7.86 per 1000 person‐year, respectively). Multivariate Cox‐regression analysis revealed that PD was an independent risk factor for AF (hazard ratio [HR]: 1.27, 95% confidence interval [CI]: 1.18–1.36). Furthermore, subgroup analyses revealed that AF risk was higher in the younger age subgroups, and compared with the non‐PD group, the youngest PD group (age: 40–49 years) had a threefold increased risk of AF (HR: 3.06, 95% CI: 1.20–7.77).InterpretationPatients with PD, especially the younger age subgroups, have an increased risk of AF. Active surveillance and management of AF should be considered to prevent further complications.

Section: Methodsmentioning

confidence: 99%

Increased atrial fibrillation risk in Parkinson’s disease: A nationwide population‐based study

Han

Moon

et al. 2021

Ann Clin Transl Neurol

Self Cite

“…This was a nationwide retrospective observational cohort study utilizing Korean National Health Insurance claims data from the Health Insurance Review and Assessment (HIRA) database, which contains demographic and medical claims information of more than 50 million Koreans 12 , 13 . South Korea has a single-payer, universal, and compulsory health insurance system, covering approximately 98% of the entire Korean population.…”

Section: Methodsmentioning

confidence: 99%

“…Diagnoses were coded using the International Classification of Diseases, Tenth Revision (ICD-10), Clinical Modification codes. The claims database based on the Korean HIRA did not include the laboratory data 12 . This study was approved by the Institutional Review Board of Seoul National University Hospital (E-1811-002-982).…”

Section: Methodsmentioning

confidence: 99%

Comparative clinical outcomes of dronedarone and sotalol in Asian patients with atrial fibrillation: a nationwide cohort study

Lee

Kim

et al. 2020

Sci Rep

Self Cite

We aimed to evaluate the effectiveness and safety of dronedarone versus sotalol in real-world practice in Asian patients with atrial fibrillation (AF). Using the Korean nationwide claims database from August 2013 to December 2016, we identified patients with AF recently prescribed dronedarone or sotalol and analyzed the hospitalization risk and all-cause death until December 2017. Overall, 3119 and 1575 patients treated with dronedarone and sotalol, respectively, were included. After propensity score weighting, no significant differences were observed between the treatment groups. Dronedarone use was associated with a lower risk of all-cause hospitalization than sotalol use (hazard ratio [HR], 0.79; 95% confidence interval [CI], 0.70–0.88). The dronedarone group demonstrated a significantly lower risk of cardiovascular (CV) hospitalization than the sotalol group (HR 0.62, 95% CI 0.53–0.72); however, no significant difference was observed in non-CV hospitalization. No difference in the risk of all-cause death was observed between groups. The dronedarone group was significantly less likely to receive nonpharmacological treatment for AF than the sotalol group (HR 0.63, 95% CI 0.51–0.77). In a large-scale population of Asian patients with AF, dronedarone was associated with a lower risk of CV hospitalization and a lower need for nonpharmacological treatment for AF than sotalol.

“…The NHIS is a mandatory health insurance program managed by the Korean government that covers the majority (97%) of the Korean population. Records from the NHIS database include sociodemographic information, medical treatment, and disease diagnosed according to the International Classification of Disease-10 (ICD-10) 10 .…”

Section: Methodsmentioning

confidence: 99%

Chromosomal abnormalities and atrial fibrillation and ischemic stroke incidence: a nationwide population-based study

Cho

Moon

et al. 2020

Sci Rep

Self Cite

There is a paucity of information as to whether chromosomal abnormalities, including Down Syndrome, Turner Syndrome, and Klinefelter Syndrome, have an association with atrial fibrillation (AF) and ischemic stroke development. Data from 3660 patients with Down Syndrome, 2408 with Turner Syndrome, and 851 with Klinefelter Syndrome without a history of AF and ischemic stroke were collected from the Korean National Health Insurance Service (2007–2014). These patients were followed-up for new-onset AF and ischemic stroke. Age- and sex-matched control subjects (at a ratio of 1:10) were selected and compared with the patients with chromosomal abnormalities. Down Syndrome patients showed a higher incidence of AF and ischemic stroke than controls. Turner Syndrome and Klinefelter Syndrome patients showed a higher incidence of AF than did the control group, but not of stroke. Multivariate Cox regression analysis revealed that three chromosomal abnormalities were independent risk factors for AF, and Down Syndrome was independently associated with the risk of stroke. In conclusion, Down Syndrome, Turner Syndrome, and Klinefelter Syndrome showed an increased risk of AF. Down Syndrome patients only showed an increased risk of stroke. Therefore, AF surveillance and active stroke prevention would be beneficial in patients with these chromosomal abnormalities.